Healthcare
Climb Biotherapeutics, Inc.(CLYM)
Live Price
Offline$11.45
+0.97% today
1Y Change
+780.77%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $780.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +42.5%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Climb Biotherapeutics, Inc. (CLYM) is a Healthcare stock with a market cap of $780.00M and listed on NASDAQ. The stock last traded around $11.45 and up 780.8% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +42.5%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +42.5%, free cash flow -250.5% with operating margin 0.0% and ROIC -42.2%. Stock Foundry combines CLYM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +42.5%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.6% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | -0.7% | -7.8% | -4.4% |
2026 Mar 5, 2026 | -30.0% | -2.8% | -1.8% | -11.2% |
2025 Nov 6, 2025 | -18.8% | -6.2% | -4.1% | -11.8% |
Benchmark Edge
CLYM vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CLYM
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CLYM Max Drawdown
-33.87%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CLYM and SPY.
Company Overview
Climb Biotherapeutics, Inc.
NASDAQ
Climb Biotherapeutics, Inc. is a company in the biotechnology industry, focusing on the development and commercialization of novel therapeutic solutions. Primarily, it plays a role in advancing treatments for conditions that lack efficient medical solutions, positioning itself at the forefront of innovation in health care. The company's research and product pipeline frequently encompasses diverse therapeutic areas, leveraging cutting-edge technology and research methodologies to target complex biological processes. Climb Biotherapeutics impacts sectors such as pharmaceuticals, medical research, and health services, contributing vital new approaches that could transform patient care standards. Within the financial markets, it holds significance as a biotech entity potentially providing new breakthroughs that may influence industry standards and economic evaluations. By aiming to tackle unmet medical needs, Climb Biotherapeutics is a key player in potentially altering disease management protocols and enhancing health outcomes, thus maintaining a critical role in both the scientific community and the financial ecosystem where health innovation is a focal point of interest.
- Leadership
- Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc
- Employees
- 28
- Street Address
- 20 William Street, Suite 145
- Mailing
- Wellesley Hills, MA, 02481
- Region
- Wellesley Hills, MA, United States
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 4.8
Growth
- Revenue
- 0.0%
- EPS
- +42.5%
- Free Cash Flow
- -250.5%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -33.4%
- ROIC
- -42.2%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 15.16
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.